MTOR and cancer: Together, these results demonstrate a critical role for mTOR in HSPC survival and suggest that potential BM suppression should be a viable concern for patients who are considering of taking dual mTORC1/2 inhibitors either alone or in combination with other chemotherapeutic agents in the course of cancer treatment.